Kikuchi fujimoto disease: a case report

Kikuchi-Fujimoto hastalığı veya histiyositik nekrotizan lenfadenit (HNL) özellikle ortalama 30 yas civarındaki bayanlarda görülen kendiliğinden sınırlanan, nekrotizan servikal lenfadenopati ile karakterize bir hastalıktır. Ates, titreme, kas ve eklem ağrısı, splenomegali ve deride döküntüleri kliniğe eşlik edebilir. Hastalık bir-üç ay içinde kendiliğinden düzelir.Asya'da daha yaygın olmakla beraber bütün dünyada görülebilir. Yirmi yasında, servikal lenfadenopati ve ateş şikayeti olan, eksizyonel lenf nodu biyopsisinde ve patolojik Değerlendirilmesinde HNL tanısı konulan bir erkek hasta sunuldu. HNL hastalığı benin lenfadenopatinin nadir nedenlerinden biridir. Benign, etyolojisi bilinmeyen bu hastalık yaygın olarak lenfoma yanlış tanısını alır. Kendiliğinden sınırlanan bu klinik tablo benign lenfadenopatilerin ayırıcı tanısında gözardı edilmemelidir.Kikuchi-Fujimoto disease or Histiocytic necrotizing lymphadenitis (HNL) is a self-limited disorder characterized by necrotizing cervical lymphadenopathy in especially women (with a mean age of 30 years). It presents with fever, chills, myalgias, arthralgias, splenomegaly, and skin rashes. The disease usually resolves within 1-3 months. It is most common inAsia but has been described worldwide. We present a 20 years old man with complaints of cervical lymphadenopathy and fever, whom diagnosed as Kikuchi-Fujimoto disease with excisional lymph node biopsy and pathological inspection. HNLdisease is one of the rarest causes of benign lymphadenopathy. This disease, whose etiology is not known, is commonly misdiagnosed as lymphoma. This self-limiting disease should be kept in mind in differential diagnosis of benign lymphadenopathies

In a real-life setting, direct-acting antivirals to people who inject drugs with chronic hepatitis c in Turkey

Background: People who inject drugs (PWID) should be treated in order to eliminate hepatitis C virus in the world. The aim of this study was to compare direct-acting antivirals treatment of hepatitis C virus for PWID and non-PWID in a real-life setting. Methods: We performed a prospective, non-randomized, observational multicenter cohort study in 37 centers. All patients treated with direct-acting antivirals between April 1, 2017, and February 28, 2019, were included. In total, 2713 patients were included in the study among which 250 were PWID and 2463 were non-PWID. Besides patient characteristics, treatment response, follow-up, and side effects of treatment were also analyzed. Results: Genotype 1a and 3 were more prevalent in PWID-infected patients (20.4% vs 9.9% and 46.8% vs 5.3%). The number of naïve patients was higher in PWID (90.7% vs 60.0%), while the number of patients with cirrhosis was higher in non-PWID (14.1% vs 3.7%). The loss of follow-up was higher in PWID (29.6% vs 13.6%). There was no difference in the sustained virologic response at 12 weeks after treatment (98.3% vs 98.4%), but the end of treatment response was lower in PWID (96.2% vs 99.0%). In addition, the rate of treatment completion was lower in PWID (74% vs 94.4%). Conclusion: Direct-acting antivirals were safe and effective in PWID. Primary measures should be taken to prevent the loss of follow-up and poor adherence in PWID patients in order to achieve World Health Organization’s objective of eliminating viral hepatitis

Actin Reorganization in Shigella Species

Shigella spp., the cause shigellosis are immotile gram-negative microorganisms. Actin reorganization is very important for motility and infection pathogenesis with Shigella spp

Efficacy and safety of direct-acting antivirals in elderly patients with chronic Hepatitis C: A nationwide real-life, observational, multicenter study from Turkey

Background: The number and proportion of elderly patients living with chronic hepatitis C are expected to increase in the coming years. We aimed to compare the real-world efficacy and safety of direct-acting antiviral treatment in elderly and younger Turkish adults infected with chronic hepatitis C. Methods: In this multicenter prospective study, 2629 eligible chronic hepatitis C patients treated with direct-acting antivirals between April 2017 and December 2019 from 37 Turkish referral centers were divided into 2 age groups: elderly (≥65 years) and younger adults (<65 years) and their safety was compared between 2 groups in evaluable population. Then, by matching the 2 age groups for demographics and pretreatment risk factors for a non-sustained virological response, a total of 1516 patients (758 in each group) and 1244 patients (622 in each group) from the modified evaluable population and per-protocol population were included in the efficacy analysis and the efficacy was compared between age groups. Results: The sustained virological response in the chronic hepatitis C patients was not affected by the age and the presence of cirrhosis both in the modified evaluable population and per-protocol population (P = .879, P = .508 for modified evaluable population and P = .058, P = .788 for per-protocol population, respectively). The results of the per-protocol analysis revealed that male gender, patients who had a prior history of hepatocellular carcinoma, patients infected with non-genotype 1 hepatitis C virus, and patients treated with sofosbuvir+ribavirin had a significantly lower sustained virological response 12 rates (P < .001, P = .047, P = .013, and P = .025, respectively). Conclusion: Direct-acting antivirals can be safely used to treat Turkish elderly chronic hepatitis C patients with similar favorable efficacy and safety as that in younger adults